The Hindu Business Line : Ranbaxy arm buys production unit from US company

IN yet another buy-out, Ranbaxy Laboratories has acquired a liquid manufacturing facility from the New York-based Signature Pharmaceuticals Inc on an asset purchase basis through its wholly-owned subsidiary, Ranbaxy Pharmaceuticals Inc, US.

In an announcement made here today, Ranbaxy said that the fully automated manufacturing and packaging line facility with the latest testing and quality assurance capabilities, would be the first liquid manufacturing unit of the pharma major in the US.

The acquisition would also bring in advanced capabilities for research, development, manufacturing and distribution of controlled substances, the statement said.

This acquisition, Ranbaxy said, would be a strategic fit for its business in the US for the production of certain liquid-based dosage forms that would enable in-house manufacture and strengthen its liquid product pipeline.

It would result in cost savings with respect to products which are currently outsourced and also exhibit validation services for Ranbaxy's products in the US.

The Ranbaxy statement makes no mention of the consideration at which the deal was inked between the two parties.

In September 1995, Ranbaxy acquired Ohm Laboratories which has provided advanced manufacturing capabilities and processes to make `over-the-counter' (OTC) drugs, branded and generic products.

Send this article to Friends by E-Mail

Stories in this Section
Maruti slashes prices of 800 cc models

Tata Engg's Indica to sport a higher price tag `soon'

Honda Motorcycle's Dio set for September debut

Laws complied with on ALBM, says Reliance

Hero Honda to seek shareholders' nod to hike FII limit

Sierra Optima is now arm of US co, changes name

New-look Qualis to hit the road in September

Essar clarifies on RS discussion

Wipro licence for Emuzed

Corporate malfeasance cowers markets

M&M completes Sintered sell-off